Mirabet 50mg is the standard maintenance dose of mirabegron for adults with overactive bladder (OAB) who have tolerated the 25mg starting dose for 4 to 8 weeks. It reduces urgency, urinary frequency, and urge incontinence by relaxing the detrusor muscle of the bladder. Buy Mirabet 50mg online at PakMeds and save on genuine, prescription verified medicine delivered to your door.

Mirabet 50mg Ingredients and Usage

Mirabet 50mg contains mirabegron — a selective beta-3 adrenergic receptor (β3-AR) agonist and the first drug in its class approved by the FDA for overactive bladder. It treats the three core OAB symptoms: urinary urgency, urge urinary incontinence, and increased urinary frequency. Mirabet 50mg is also used in combination with solifenacin (a muscarinic antagonist) for patients requiring stronger dual mechanism OAB control.

Mirabet 50mg is the standard therapeutic maintenance dose — prescribed after tolerability is confirmed at 25mg over 4 to 8 weeks. It is not appropriate as an initial dose. Mirabet 50mg must not be used in patients with severe renal impairment (eGFR 15–29 mL/min), moderate hepatic impairment (Child-Pugh B), or severe hepatic impairment (Child-Pugh C) — these patients must not exceed 25mg per day.

How Does Mirabet 50mg Work?

Mirabet 50mg works by selectively activating beta-3 adrenergic receptors (β3-ARs) in the detrusor — the smooth muscle layer of the bladder wall. β3-AR stimulation triggers a cyclic AMP mediated cascade that causes the detrusor to relax during bladder filling, directly increasing the volume of urine the bladder can hold before the urge to void is triggered. At 50mg, peak plasma concentrations are approximately double those achieved at 25mg, delivering stronger detrusor relaxation and greater symptom control.

Unlike antimuscarinic OAB drugs, mirabegron does not block muscarinic receptors in the salivary glands or bowel. This produces up to six times less dry mouth than antimuscarinics — a key advantage for long term tolerability and patient adherence. Mirabet 50mg also avoids the cognitive impairment and constipation side effects common with older OAB medicines.

Mirabet 50mg Side Effects

Mirabet 50mg is well tolerated in most patients. In FDA registration trials across 2,736 OAB patients, the most commonly reported adverse effects for the 50mg dose were:

• Hypertension — reported in 7.5% of patients on 50mg versus 7.6% on placebo; monitor blood pressure periodically
• Nasopharyngitis — reported in 3.9% of patients; upper respiratory cold-like symptoms
• Urinary tract infection (UTI) — reported in 2.9% of patients; report burning or pain on urination promptly
• Headache — reported in 3.2% of patients at the 50mg dose
• Tachycardia and palpitations — elevated heart rate; more likely at 50mg than 25mg
• Back pain and joint pain — musculoskeletal effects reported in post-marketing data
• Dizziness, nausea, and diarrhea — reported in post-marketing surveillance
• Confusion, insomnia, or anxiety — rare post-marketing reports; inform your doctor if these develop
• Elevated liver enzymes (ALT/AST) — reversible increases reported in a small number of 50mg patients in clinical trials

Warnings

• Severe uncontrolled hypertension — contraindicated: Do not use Mirabet in patients with systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg. Monitor blood pressure periodically throughout treatment, especially in patients with pre-existing hypertension.
• Hypersensitivity — contraindicated: Mirabet is contraindicated in patients with a known allergic reaction to mirabegron or any tablet excipient. Discontinue immediately and seek medical care if a reaction develops.
• Angioedema: Post-marketing reports document angioedema of the face, lips, tongue, and larynx — a potentially life-threatening reaction. Discontinue Mirabet 50mg immediately and call emergency services if swelling of the mouth or throat develops.
• Urinary retention: Mirabet can cause urinary retention in patients with bladder outlet obstruction. Use with caution in patients with benign prostatic hyperplasia. Risk is highest when Mirabet 50mg is combined with antimuscarinic OAB drugs — monitor for decreased urine output.
• CYP2D6 drug interactions: Mirabegron is a moderate CYP2D6 inhibitor at 50mg. It raises plasma levels of metoprolol, desipramine, thioridazine, flecainide, and propafenone. Dose adjustment and close monitoring are required for all narrow therapeutic index CYP2D6 substrates.
• Digoxin interaction: Initiate with the lowest available digoxin dose when starting Mirabet 50mg. Monitor serum digoxin concentrations regularly and titrate to the desired clinical effect.
• CYP3A4 inhibitors: Strong CYP3A4 inhibitors such as ketoconazole increase mirabegron plasma exposure by up to 80%. Use with caution and consider dose reduction to 25mg if concurrent use is unavoidable.
• Not for severe renal or hepatic impairment: Mirabet 50mg must not be used in patients with severe renal impairment (eGFR 15–29 mL/min), moderate hepatic impairment (Child-Pugh B), or severe hepatic impairment (Child-Pugh C). The maximum safe dose in these patients is 25mg per day.
• Liver enzyme monitoring: Reversible ALT/AST elevations above 10-fold baseline were observed in 0.3% of patients on 50mg in clinical trials. Monitor liver function in patients with pre-existing liver conditions.
• Pregnancy: Insufficient safety data exist for mirabegron use during pregnancy. Use only if the potential benefit clearly outweighs the risk to the fetus. Consult your doctor before starting Mirabet 50mg.
• Breastfeeding: Mirabegron is found in the milk of lactating animals. Human excretion data are insufficient. Discuss risks and alternatives with your doctor before breastfeeding while on Mirabet 50mg.

Mirabet 50mg Storage Conditions

• Store below 30°C at room temperature
• Protect from direct heat, sunlight, and moisture at all times
• Keep in the original packaging until use
• Do not store in the bathroom — humidity degrades extended release tablets
• Keep out of reach of children at all times
• Dispose of expired or unused tablets as directed by your pharmacist — do not flush or discard in household waste

Mirabet 50mg Price in Pakistan

Mirabet 50mg is available in Pakistan at approximately Rs. 1,400 to Rs. 1,802 per pack of 20 tablets. Ailaaj lists the pack at around Rs. 1,400 while Smarthealer prices it at Rs. 1,802. Prices vary across pharmacies and may change with availability.

Mirabet is a specialist urology medicine with limited generic competition in Pakistan at this time. PakMeds stocks genuine CCL Pharmaceuticals Mirabet 50mg with fast, verified delivery nationwide — order Mirabet 50mg at PakMeds today and save on your ongoing OAB treatment.

Mirabet 50mg — Frequently Asked Questions

When is Mirabet 50mg prescribed instead of 25mg?

Mirabet 50mg is prescribed when a patient has tolerated the 25mg starting dose for 4 to 8 weeks but has not achieved sufficient OAB symptom control. The prescribing urologist assesses urgency episodes, incontinence frequency, and micturition diary data before escalating. It is never used as an initial dose.

Not all patients require escalation — many achieve adequate symptom control at 25mg. Patients with severe renal impairment or moderate hepatic impairment must remain on 25mg regardless of OAB severity. If 50mg does not provide adequate control after a further 4 to 8 weeks, your urologist may consider adding solifenacin as a combination approach.

How should Mirabet 50mg tablets be taken?

Take one Mirabet 50mg tablet once daily, with or without food, at the same time each day. Swallow the tablet whole with a full glass of water — do not crush, chew, or break it, as this destroys the extended release mechanism. If taking Mirabet alongside solifenacin, take both medicines at the same time each day.

If you miss a dose, take it as soon as you remember on the same day. If it is almost time for the next dose, skip the missed dose and resume your regular schedule. Do not double up doses. Consistent daily dosing at the same time maintains stable plasma levels and delivers the most reliable OAB symptom control.

Can Mirabet 50mg be taken long term for overactive bladder?

Yes — Mirabet 50mg is designed for long term OAB management. Clinical evidence supports continuous use for sustained reductions in urgency, frequency, and incontinence episodes. Regular follow-up with your urologist every 3 to 6 months is recommended to monitor blood pressure, kidney function, and treatment efficacy.

Patients on long term Mirabet 50mg should monitor their blood pressure at home, especially if they have pre-existing hypertension. Liver enzyme levels should be checked periodically, as reversible ALT/AST elevations have been documented in a small number of long term users. Report any new symptoms — including chest tightness, palpitations, or swelling — to your doctor promptly.